The Pharmaceutical Industry in in transition:
*$60 billion of US pharma patent revenue will expire in 2012
*Decline in FDA drug approvals
*Surge of the generics which now accounts for 3 in 4 pills
*Shift to the stakeholder payer model puts market access at centre stage
*Leaner and more agile pharma companies
*50,000+ senior level redundancies in the US alone
*Even more pressure on those retained
*Huge opportunities in emerging markets
wtf?
001001sith 6 months ago